Vericel Co. (NASDAQ:VCEL) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Vericel Co. (NASDAQ:VCELGet Free Report) have been assigned an average rating of “Buy” from the seven brokerages that are covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have covered the stock in the last year is $57.71.

VCEL has been the topic of several research reports. Stephens boosted their price objective on shares of Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Vericel in a research report on Friday, November 8th. Canaccord Genuity Group began coverage on shares of Vericel in a report on Friday, August 9th. They set a “buy” rating and a $57.00 target price for the company. TD Cowen boosted their price target on Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, August 27th. Finally, Canaccord Genuity Group assumed coverage on shares of Vericel in a research report on Friday, August 9th. They set a “buy” rating and a $57.00 target price on the stock.

Check Out Our Latest Stock Report on VCEL

Insider Buying and Selling

In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total value of $724,150.00. Following the completion of the transaction, the chief executive officer now directly owns 220,937 shares in the company, valued at approximately $9,142,373.06. This represents a 7.34 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Steven C. Gilman sold 5,833 shares of the stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total value of $235,361.55. Following the completion of the sale, the director now owns 11,000 shares of the company’s stock, valued at $443,850. The trade was a 34.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,166 shares of company stock worth $1,200,764 in the last ninety days. 5.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Vericel

A number of hedge funds have recently made changes to their positions in VCEL. Swiss National Bank increased its position in shares of Vericel by 0.4% during the first quarter. Swiss National Bank now owns 89,500 shares of the biotechnology company’s stock worth $4,656,000 after buying an additional 400 shares during the period. Sei Investments Co. grew its stake in shares of Vericel by 49.4% in the 1st quarter. Sei Investments Co. now owns 49,340 shares of the biotechnology company’s stock worth $2,567,000 after acquiring an additional 16,312 shares in the last quarter. ProShare Advisors LLC grew its position in Vericel by 8.3% in the 1st quarter. ProShare Advisors LLC now owns 12,985 shares of the biotechnology company’s stock worth $675,000 after purchasing an additional 995 shares in the last quarter. State Board of Administration of Florida Retirement System grew its holdings in shares of Vericel by 19.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 16,199 shares of the biotechnology company’s stock valued at $843,000 after acquiring an additional 2,600 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Vericel by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 3,413,442 shares of the biotechnology company’s stock valued at $177,567,000 after purchasing an additional 39,349 shares during the last quarter.

Vericel Trading Up 0.8 %

NASDAQ:VCEL opened at $52.89 on Tuesday. The firm has a market capitalization of $2.61 billion, a price-to-earnings ratio of 881.65 and a beta of 1.66. The business’s 50-day moving average price is $44.92 and its two-hundred day moving average price is $46.70. Vericel has a 1-year low of $32.31 and a 1-year high of $57.81.

Vericel (NASDAQ:VCELGet Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The business had revenue of $57.91 million for the quarter, compared to the consensus estimate of $55.32 million. Sell-side analysts predict that Vericel will post 0.13 earnings per share for the current year.

About Vericel

(Get Free Report

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

Featured Stories

Analyst Recommendations for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.